<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00647998</url>
  </required_header>
  <id_info>
    <org_study_id>DISC-001</org_study_id>
    <nct_id>NCT00647998</nct_id>
  </id_info>
  <brief_title>The Darbepoetin Alfa for Ischemic Surgical Complications (DISC) Dose Finding Trial</brief_title>
  <acronym>DISC</acronym>
  <official_title>Phase 2 Dose Finding Trial of Prophylactic Darbepoetin Alfa to Improve Outcomes From Ischemic Complications of Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Numerous neuroprotectants have been effective when given prior to ischemic stroke in animals,
      yet they have all have failed when given after ischemic stroke in humans. A novel approach to
      ischemic neuroprotection is needed. Many patients who undergo cardiac, vascular, and
      neurosurgical procedures develop ischemic central nervous system (CNS) complications. These
      high risk surgeries present a unique opportunity to administer neuroprotectant medication
      prior to the injury, greatly increasing the likelihood that it will have a positive impact on
      outcomes. Patients undergoing descending thoracic aortic (DTA) and thoracoabdominal aortic
      (TAA) surgery have a particularly high rate of both brain and spine ischemia. In addition,
      these surgeries require placement of a lumbar cerebrospinal fluid (CSF) drain, allowing
      access to CSF in order to monitor markers of injury and penetration of medication into the
      CNS. We are performing a pilot dose finding trial of prophylactic darbepoetin alfa, a
      long-acting erythropoiesis medication with putative neuroprotectant properties, in patients
      undergoing DTA and TAA surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Numerous neuroprotectants have been effective when given prior to ischemic stroke in animals,
      yet they have all have failed when given after ischemic stroke in humans. A novel approach to
      ischemic neuroprotection is needed. Many patients who undergo cardiac, vascular, and
      neurosurgical procedures develop ischemic central nervous system (CNS) complications. These
      high risk surgeries present a unique opportunity to administer neuroprotectant medication
      prior to the injury, greatly increasing the likelihood that it will have a positive impact on
      outcomes. Patients undergoing descending thoracic aortic (DTA) and thoracoabdominal aortic
      (TAA) surgery have a particularly high rate of both brain and spine ischemia. In addition,
      these surgeries require placement of a lumbar cerebrospinal fluid (CSF) drain, allowing
      access to CSF in order to monitor markers of injury and penetration of medication into the
      CNS. We performed a pilot dose finding trial of prophylactic darbepoetin alfa, a long-acting
      erythropoiesis medication with putative neuroprotectant properties, in patients undergoing
      DTA and TAA surgery. This dose finding trial was stopped early after 9 patients were enrolled
      at the request of the FDA after an unrelated trial of erythropoietin in acute stroke
      performed in Germany was negative and showed possible harm in those patients who received
      intravenous tissue plasminogen activaor (tPA). We then enrolled 9 additional patients who did
      not receive any intervention in order to compare them to the patients who received
      darbepoetin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death or Neurologic Disability, Defined as an National Institutes of Health Stroke Scale (NIHSS)&gt;4 or American Spinal Injury Association (ASIA) Lower Extermity Motor Score &lt;25</measure>
    <time_frame>Discharge from the hospital</time_frame>
    <description>The NIHSS is a validated quasi-ordinal measure of stroke severity. An NIHSS &gt;4 is generally considered moderate or severe. The ASIA Lower Extremity Motor Score is a cumulative total of assessments of strength in 5 muscles in each leg, using the Medical Research Council 0-5 stroke score. ASIA score &lt; 25 is associated with impaired ambulation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CSF S100beta</measure>
    <time_frame>48 hours</time_frame>
    <description>Cerebrospinal fluid S100beta level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>24 hours post-surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Spinal Ischemia</condition>
  <condition>Stroke</condition>
  <condition>Neuroprotection</condition>
  <arm_group>
    <arm_group_label>Darbepoetin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received 1mg/kg IV Darbepoetin immediately prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No Darbepoetin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin alfa</intervention_name>
    <description>Patients will receive one IV injection of Darbepoetin alfa at doses ranging from 1mcg/kg to 6.5 mcg/kg prior to surgery</description>
    <arm_group_label>Darbepoetin</arm_group_label>
    <other_name>Aranesp</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard care</intervention_name>
    <arm_group_label>Darbepoetin</arm_group_label>
    <arm_group_label>Standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are men and women between the ages of 18 - 100 years old (inclusive)

          -  Require descending thoracic or thoracoabdominal aorta surgical repair

          -  Can provide informed consent

        Exclusion Criteria:

          -  Have a traumatic aortic dissection

          -  Have a baseline NIHSS &gt; 1 or modified Rankin Scale &gt; 1

          -  Have a history of stroke or myocardial infarction within the past 30 days

          -  Have a preoperative hemoglobin &lt; 9 or &gt; 14

          -  Have a history of polycythemia vera or essential thrombocytosis

          -  Have a history of hematologic malignancy

          -  Have a history of arterial or venous thrombosis in the past three months

          -  Have uncontrolled hypertension

          -  Have active malignancy requiring treatment

          -  Are receiving hemodialysis

          -  Are currently using recombinant human erythropoietin or darbepoetin alfa, or have an
             expectation to require these medications within 30 days of surgery.

          -  Have a known allergy to recombinant human erythropoietin or darbepoetin alfa

          -  Are pregnant or breast-feeding. Women of childbearing potential must have a negative
             pregnancy test (urine pregnancy test or serum beta-HCG)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <results_first_submitted>November 3, 2016</results_first_submitted>
  <results_first_submitted_qc>November 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 2, 2017</results_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Steven Messe</investigator_full_name>
    <investigator_title>Associate professor of neurology</investigator_title>
  </responsible_party>
  <keyword>Surgical complications</keyword>
  <keyword>Spinal ischemia</keyword>
  <keyword>Stroke</keyword>
  <keyword>Neuroprotection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Darbepoetin Alfa</title>
          <description>Patients receive 1 mg/kg IV darbepoetin immediately before surgery</description>
        </group>
        <group group_id="P2">
          <title>Standard Care</title>
          <description>No darbepoetin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Darbepoetin Alfa</title>
          <description>Patients receive 1 mg/kg IV darbepoetin immediately before surgery</description>
        </group>
        <group group_id="B2">
          <title>Standard Care</title>
          <description>No darbepoetin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="55" upper_limit="67"/>
                    <measurement group_id="B2" value="62" lower_limit="58" upper_limit="64"/>
                    <measurement group_id="B3" value="59" lower_limit="55" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior stroke</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior aortic surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Death or Neurologic Disability, Defined as an National Institutes of Health Stroke Scale (NIHSS)&gt;4 or American Spinal Injury Association (ASIA) Lower Extermity Motor Score &lt;25</title>
        <description>The NIHSS is a validated quasi-ordinal measure of stroke severity. An NIHSS &gt;4 is generally considered moderate or severe. The ASIA Lower Extremity Motor Score is a cumulative total of assessments of strength in 5 muscles in each leg, using the Medical Research Council 0-5 stroke score. ASIA score &lt; 25 is associated with impaired ambulation.</description>
        <time_frame>Discharge from the hospital</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa</title>
            <description>Patients receive 1 mg/kg IV darbepoetin immediately before surgery</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>No darbepoetin</description>
          </group>
        </group_list>
        <measure>
          <title>Death or Neurologic Disability, Defined as an National Institutes of Health Stroke Scale (NIHSS)&gt;4 or American Spinal Injury Association (ASIA) Lower Extermity Motor Score &lt;25</title>
          <description>The NIHSS is a validated quasi-ordinal measure of stroke severity. An NIHSS &gt;4 is generally considered moderate or severe. The ASIA Lower Extremity Motor Score is a cumulative total of assessments of strength in 5 muscles in each leg, using the Medical Research Council 0-5 stroke score. ASIA score &lt; 25 is associated with impaired ambulation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CSF S100beta</title>
        <description>Cerebrospinal fluid S100beta level</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin</title>
            <description>Patients received 1mg/kg IV Darbepoetin immediately prior to surgery
Darbepoetin alfa: Patients will receive one IV injection of Darbepoetin alfa at doses ranging from 1mcg/kg to 6.5 mcg/kg prior to surgery
Standard care</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>No Darbepoetin
Standard care</description>
          </group>
        </group_list>
        <measure>
          <title>CSF S100beta</title>
          <description>Cerebrospinal fluid S100beta level</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214" lower_limit="118" upper_limit="235"/>
                    <measurement group_id="O2" value="260" lower_limit="68" upper_limit="1175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin</title>
        <time_frame>24 hours post-surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa</title>
            <description>Patients receive 1 mg/kg IV darbepoetin immediately before surgery</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>No darbepoetin</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin</title>
          <units>gm/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" spread="2.1"/>
                    <measurement group_id="O2" value="9.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Darbepoetin Alfa</title>
          <description>Patients receive 1 mg/kg IV darbepoetin immediately before surgery</description>
        </group>
        <group group_id="E2">
          <title>Standard Care</title>
          <description>No darbepoetin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Spinal ischemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steven Messe, MD</name_or_title>
      <organization>Hospital of the University of Pennsylvania</organization>
      <phone>2156623363</phone>
      <email>messe@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

